Prostate cancer that stops responding to androgen receptor–targeted therapies remains one of the most lethal challenges in oncology, and a new study from Duke University and Xavier University of Louisiana suggests that the next generation of antibody–drug conjugates may fight this disease in ways that go far beyond simple tumor killing. Published in the Journal of Translational Medicine, the research describes a prostate cancer–specific antibody–drug conjugate platform built around vandortuzumab, an antibody directed against the six transmembrane epithelial antigen of the prostate 1, or STEAP1, a surface protein that is largely restricted to prostate-lineage tissue and regulated by the androgen receptor. The team’s central finding is striking: the most effective constructs were not simply the ones that delivered the most potent cytotoxic payload to tumor cells, but the ones that deliberately engaged the immune system, triggering antigen presentation and T-cell activation that produced durable tumor control and long-lasting immune memory in preclinical models.
The clinical context motivating the work is sobering. Patients whose disease progresses after treatment with androgen pathway modulators, chemotherapy, and PSMA-directed radioligand therapy face limited options and typically fatal outcomes. Antibody–drug conjugates have transformed treatment in several other malignancies by coupling monoclonal antibodies to potent payloads through chemical linkers, allowing cytotoxic drugs to be delivered preferentially to antigen-expressing tumor cells. However, as the Duke team points out, ADCs evaluated so far in metastatic androgen pathway modulation resistant prostate cancer have been designed and assessed almost exclusively on their ability to kill tumor cells directly, without asking whether immune mechanisms might underpin the most durable responses seen in the clinic. Whether immune activation contributes to ADC efficacy in prostate cancer at all had remained an open and unexplored question, and it is precisely this question the study set out to answer.
The design strategy was deliberately immune-centric from the start. STEAP1 was chosen as the target because of its favorable biology: it sits on the cell surface of prostate cancer cells, its expression is driven by androgen receptor signaling, and its distribution outside the prostate lineage is minimal, reducing the risk of off-tumor toxicity that has plagued some ADC programs. The investigators generated a panel of vandortuzumab-based ADCs by conjugating the antibody to payloads across multiple clinically validated linker–payload platforms, allowing head-to-head comparison of how different payload chemistries affect not only direct cytotoxicity but also the immunological consequences of tumor cell death. This comparative approach is important because growing evidence in other cancers suggests that certain classes of payloads, particularly topoisomerase I inhibitors, can promote immunogenic cell death, a form of tumor cell killing that releases antigen and danger signals capable of priming adaptive immune responses rather than the quiet, immunologically silent apoptosis produced by many conventional cytotoxics.
The experimental pipeline combined sophisticated in vitro assays with two distinct in vivo model systems. In cell culture, the team measured Fcγ receptor engagement, the process by which the antibody’s Fc region binds to activating Fc receptors on myeloid cells such as macrophages and dendritic cells, and they tracked how this engagement influenced antigen presentation and downstream T-cell activation. The results revealed a mechanistic hierarchy that had not previously been appreciated in prostate cancer ADC development. Fcγ receptor engagement proved to be required for optimal antigen presentation by myeloid cells and for the downstream activation of T cells, meaning the antibody backbone itself, through its immune-recruiting Fc domain, plays an active role in turning drug-induced tumor death into an immune stimulus. In other words, the ADC is not just a delivery vehicle but a participant in the immune response it ultimately generates.
Among the payloads tested, exatecan-based conjugates demonstrated the strongest immunostimulatory activity. Exatecan is a potent topoisomerase I inhibitor that has attracted intense interest in recent years as a payload for next-generation ADCs in breast, lung, and gastrointestinal cancers, partly because of its membrane-permeable properties and its association with immunogenic forms of cell death. The Duke team’s data extend that rationale into prostate cancer with an added layer of mechanistic specificity: the immunostimulatory effect of vandortuzumab–exatecan depends on the Fc-mediated engagement of myeloid cells, which then present tumor antigens to T cells. This coupling of payload chemistry to innate immune engagement and adaptive immune priming offers a template for rational ADC design in which immune activation is treated as an engineered feature rather than an incidental byproduct.
The in vivo findings provided the most dramatic evidence for the platform’s potential. In a bone-metastatic model, which recapitulates the clinically devastating skeletal spread characteristic of advanced prostate cancer, vandortuzumab–exatecan mediated durable tumor control. More remarkably, in a syngeneic immunocompetent model of androgen pathway modulation resistant disease, a setting in which the animals retain fully functional immune systems, treated animals developed adaptive immune memory capable of preventing tumor rechallenge. This means that animals whose tumors had been cleared by the ADC were protected when researchers attempted to reintroduce the same cancer, a hallmark of a genuine vaccine-like immune response generated by the treatment itself. Such rechallenge protection is rarely achieved by conventional cytotoxic therapies and suggests the conjugate does more than shrink tumors; it educates the immune system to recognize and reject prostate cancer cells on subsequent encounters.
The implications for patients with advanced prostate cancer are substantial. Current PSMA-directed radioligand therapy, while effective at extending survival, delivers targeted radiation without intentionally leveraging immune activation, and resistance ultimately develops in most patients. Checkpoint immunotherapy has largely failed in metastatic castration-resistant prostate cancer outside the small subset of tumors with mismatch repair deficiency, largely because these tumors are immunologically cold, poorly infiltrated, and present few antigens to primed T cells. An ADC that kills tumor cells while simultaneously converting them into an in situ vaccine, releasing STEAP1 and other tumor antigens for uptake by Fcγ receptor–engaged macrophages and dendritic cells, could in principle warm up the tumor microenvironment and sensitize disease to checkpoint blockade or other immunotherapies. The Duke platform provides the mechanistic justification for testing such combinations.
The study also carries lessons for how ADCs across oncology are evaluated. Clinical development of ADCs in prostate cancer and beyond has traditionally relied on endpoints of radiographic response and survival, with immune endpoints largely absent from early-phase testing. By demonstrating that Fcγ receptor engagement and antigen presentation are required for optimal T-cell activation, and that different payloads sharing the same antibody target diverge sharply in their immunostimulatory capacity, the work argues that immune profiling should be incorporated into ADC design and preclinical testing from the earliest stages. Constructs that look comparable in standard cytotoxicity assays may differ profoundly in their ability to generate adaptive immune memory, and those differences could translate into the durability of response, the depth of remission, and the prevention of relapse that ultimately matter most to patients.
The research was led by John S. Wang and Zachary C. Hartman of Duke University, with contributions from a multidisciplinary team spanning Duke’s departments of Surgery, Medicine, and Pharmacology and Cancer Biology, the Duke Cancer Institute, and the Department of Chemistry at Xavier University of Louisiana, where Qiang Zhang and Guangdi Wang contributed synthetic and conjugation chemistry expertise. The work was supported by the National Institutes of Health, the Department of Defense, and the RCMI Center for Cancer and Health Disparities Research, and it was conducted under institutional animal care approval with no human participant data. The authors note that the study used the PT-09 cell line generously provided by Dr. Brian Ruffell of the Moffitt Cancer Center and relied on Duke University core facilities for flow cytometry and animal studies.
As with all preclinical research, the path from bone-metastatic mouse models to human trials involves substantial uncertainty, including questions about the therapeutic index of exatecan-based conjugates, the translatability of syngeneic model immunology to elderly, heavily pretreated patients, and the optimal sequencing with existing androgen receptor–pathway inhibitors and radioligands. Nevertheless, the study establishes proof of principle that immune activation is a determinant of ADC efficacy in androgen pathway modulation resistant prostate cancer and that vandortuzumab–exatecan functions as an immune-engaging therapeutic capable of inducing durable anti-tumor responses. If these findings hold in clinical testing, they could reshape not only how prostate cancer ADCs are built but also how the field conceives of targeted drug delivery itself, as a strategy that kills tumors and teaches the immune system to keep them dead.
Subject of Research: STEAP1-targeted antibody–drug conjugates with immunostimulatory properties for androgen pathway modulation resistant prostate cancer
Subject of Research: Medicine
Article Title: Development of a STEAP1-targeted prostate cancer specific antibody drug conjugate platform with immunostimulatory properties
Article References: Wang, J. S., Sodhi, S. S., Tsao, L.-C., Lin, G. H., Moon, N., Zhang, Q., Liu, B., Tu, V. Y., Penaranda, J., Trotter, T. N., Somarelli, J. A., Armstrong, A. J., Lyerly, H. K., Wang, G., & Hartman, Z. C. (2026). Development of a STEAP1-targeted prostate cancer specific antibody drug conjugate platform with immunostimulatory properties. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08927-z
Image Credits: AI Generated
DOI: 10.1186/s12967-026-08927-z
Keywords: antibody-drug conjugate, STEAP1, androgen pathway modulator resistant disease, immunogenic cell death, Fc-mediated effector function, macrophage antigen presentation, adaptive immune memory, bone metastasis, prostate cancer, vandortuzumab, exatecan, cancer immunotherapy
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 8, 2026). New STEAP1-targeted antibody drug conjugate boosts immune response against prostate cancer. Scienmag. https://scienmag.com/new-steap1-targeted-antibody-drug-conjugate-boosts-immune-response-against-prostate-cancer/
Nathaniel Bowman. “New STEAP1-targeted antibody drug conjugate boosts immune response against prostate cancer.” Scienmag, 8 September 2026, https://scienmag.com/new-steap1-targeted-antibody-drug-conjugate-boosts-immune-response-against-prostate-cancer/. Accessed 9 September 2026.
Nathaniel Bowman. “New STEAP1-targeted antibody drug conjugate boosts immune response against prostate cancer.” Scienmag. September 8, 2026. https://scienmag.com/new-steap1-targeted-antibody-drug-conjugate-boosts-immune-response-against-prostate-cancer/
Copy citation Download RIS
Tags: androgen receptor regulation in prostate cancerandrogen receptor-targeted therapy resistanceantibody-drug conjugates beyond cytotoxicityantibody–drug conjugate design for prostate tumorsdurable tumor control strategiesdurable tumor control via ADCsimmune activation in cancer treatmentimmune system engagement in cancer treatmentinnovative approaches in prostate cancer treatmentlong-lasting immune memory in oncologyovercoming resistance to androgen receptor therapiespreclinical models of prostate cancerpreclinical models of prostate cancer immunotherapyprostate cancer immunotherapyprostate-lineage surface proteinsSTEAP1 antibody-drug conjugatesSTEAP1-targeted antibody-drug conjugatesT-cell activation in prostate cancerT-cell activation in targeted cancer therapytargeted therapy for treatment-resistant prostate cancertumor-specific antibody platforms
